Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMURAI: SABR + Immunotherapy in Metastatic Unresected Renal Cell Carcinoma
NCT05327686Phase 2Recruiting
- Sponsor
- NRG Oncology
- Start
- Feb 2023
- Primary completion
- Jun 2028
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Nephrectomy and Radiographic Progression-Free Survival up to 8 years. Started Feb 2023; status: recruiting.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05327686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327686.